ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2026
[Research advances on the role of eosinophils in acute liver injury].
Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of eosinophils (Eos) has attracted considerable attention in acute liver injury. Animal studies have validated that eosinophils recruited to the liver through the positive feedback loop of interleukin (IL)-4/chemokine (C-C motif) ligand 24 alleviate inflammation by inhibiting interferon-γ production via IL-4/IL-13 signaling and promotes hepatocyte proliferation through heparin-binding epidermal growth factor-like growth factor/epidermal growth factor receptor. Clinical study results suggest that drug-induced liver injury and drug-induced hypersensitivity syndrome often accompany elevated Eos levels, whereas the absence of Eos elevation predicts poor prognosis. The hypotheses of "conditional transition" and "exhaustion" have been proposed based on cases where liver failure reversed after the depletion of Eos with benralizumab monoclonal antibody, suggesting that Eos may exert a protective role in the early stages of disease but become overactivated in later stages, shifting to a pathogenic role and eventually leading to functional exhaustion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.